Daniel Egan

728 total citations
22 papers, 212 citations indexed

About

Daniel Egan is a scholar working on Hematology, Genetics and Oncology. According to data from OpenAlex, Daniel Egan has authored 22 papers receiving a total of 212 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Hematology, 9 papers in Genetics and 5 papers in Oncology. Recurrent topics in Daniel Egan's work include Chronic Lymphocytic Leukemia Research (9 papers), Chronic Myeloid Leukemia Treatments (8 papers) and Acute Myeloid Leukemia Research (6 papers). Daniel Egan is often cited by papers focused on Chronic Lymphocytic Leukemia Research (9 papers), Chronic Myeloid Leukemia Treatments (8 papers) and Acute Myeloid Leukemia Research (6 papers). Daniel Egan collaborates with scholars based in United States, South Africa and France. Daniel Egan's co-authors include Jerald P. Radich, Lan Beppu, Alessandro Pastore, Wendy Stock, Musa Yılmaz, Alice S. Mims, Asad Bashey, Raya Mawad, Allen S. Yang and William Blum and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Frontiers in Oncology.

In The Last Decade

Daniel Egan

22 papers receiving 209 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Daniel Egan United States 8 127 123 79 49 33 22 212
Gabrielle T. Prince United States 9 155 1.2× 114 0.9× 82 1.0× 80 1.6× 46 1.4× 28 263
Peter Tan Australia 10 126 1.0× 55 0.4× 109 1.4× 85 1.7× 33 1.0× 18 252
Raphael Teipel Germany 8 137 1.1× 72 0.6× 59 0.7× 30 0.6× 38 1.2× 21 196
Leah Gehrs United States 7 99 0.8× 94 0.8× 37 0.5× 90 1.8× 23 0.7× 17 194
Shaowei Qiu China 10 184 1.4× 71 0.6× 180 2.3× 33 0.7× 53 1.6× 67 344
Lars Fransecky Germany 8 99 0.8× 104 0.8× 131 1.7× 33 0.7× 34 1.0× 14 267
Jean‐Valère Malfuson France 8 143 1.1× 50 0.4× 142 1.8× 32 0.7× 42 1.3× 15 250
Carmen Martínez‐Chamorro Spain 9 341 2.7× 173 1.4× 128 1.6× 38 0.8× 43 1.3× 15 383
Kaiyang Ding China 9 107 0.8× 113 0.9× 100 1.3× 46 0.9× 30 0.9× 51 241
Timon Hansen Germany 7 163 1.3× 119 1.0× 193 2.4× 59 1.2× 57 1.7× 10 296

Countries citing papers authored by Daniel Egan

Since Specialization
Citations

This map shows the geographic impact of Daniel Egan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Egan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Egan more than expected).

Fields of papers citing papers by Daniel Egan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Egan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Egan. The network helps show where Daniel Egan may publish in the future.

Co-authorship network of co-authors of Daniel Egan

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Egan. A scholar is included among the top collaborators of Daniel Egan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Egan. Daniel Egan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Alsina, Melissa, Madhav V. Dhodapkar, Jesús G. Berdeja, et al.. (2023). P871: IDECABTAGENE VICLEUCEL (IDE-CEL) IN PATIENTS WITH AN INADEQUATE RESPONSE TO FRONTLINE AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT): RESULTS FROM KARMMA-2 COHORT 2C. HemaSphere. 7(S3). e90596a3–e90596a3. 1 indexed citations
3.
4.
Davids, Matthew S., Catherine Diefenbach, Daniel Egan, et al.. (2023). A Phase 1 Study of the Oral CDK9 Inhibitor Voruciclib in Relapsed/Refractory (R/R) B-Cell Lymphoma (NHL) or Acute Myeloid Leukemia (AML). Blood. 142(Supplement 1). 4286–4286. 4 indexed citations
5.
6.
7.
LaBella, Dominic, Helmut König, Daniel Egan, et al.. (2022). The role of adjuvant chemotherapy in the management of acute promyelocytic leukemia differentiation syndrome. Frontiers in Oncology. 12. 911745–911745. 1 indexed citations
8.
9.
10.
Egan, Daniel & Jerald P. Radich. (2020). When to consider allogeneic transplant for chronic myeloid leukemia. 3(4). 1 indexed citations
11.
Yeung, Cecilia C.S., Daniel Egan, & Jerald P. Radich. (2016). New Methodologies in the Molecular Monitoring of CML. Current Hematologic Malignancy Reports. 11(2). 94–101. 2 indexed citations
12.
Chapuis, Aude G., Daniel Egan, Merav Bar, et al.. (2016). EBV-Specific Donor Cells Transduced to Express a High-Affinity WT1 TCR Can Prevent Recurrence in Post-HCT Patients with High-Risk AML. Blood. 128(22). 1001–1001. 6 indexed citations
13.
Egan, Daniel & Jerald P. Radich. (2016). Making the diagnosis, the tools, and risk stratification: More than just BCR-ABL. Best Practice & Research Clinical Haematology. 29(3). 252–263. 6 indexed citations
14.
Egan, Daniel, et al.. (2016). Molecular monitoring of chronic myeloid leukemia: present and future. Expert Review of Molecular Diagnostics. 16(10). 1083–1091. 15 indexed citations
15.
Egan, Daniel & Jerald P. Radich. (2016). Monitoring disease burden in chronic myeloid leukemia: Past, present, and future. American Journal of Hematology. 91(7). 742–746. 7 indexed citations
16.
Egan, Daniel & Jerald P. Radich. (2015). Prognosis and Molecular Monitoring in Chronic Myeloid Leukemia. Clinical Lymphoma Myeloma & Leukemia. 15. S109–S113. 1 indexed citations
17.
Egan, Daniel, Lan Beppu, & Jerald P. Radich. (2014). Patients with Philadelphia-Positive Leukemia with BCR-ABL Kinase Mutations before Allogeneic Transplantation Predominantly Relapse with the Same Mutation. Biology of Blood and Marrow Transplantation. 21(1). 184–189. 14 indexed citations
18.
Egan, Daniel, Lan Beppu, & Jerald P. Radich. (2013). Patients With Philadelphia-Positive Leukemia With BCR-ABL Kinase Mutations Prior To Allogeneic Transplantation Predominantly Relapse With The Same Mutation. Blood. 122(21). 4043–4043. 1 indexed citations
19.
Buckley, Sarah, Daniel Egan, & Roland B. Walter. (2012). Hemophagocytic Lymphohistiocytosis in Adults: A Case Series of 30 Patients At a U.S. Tertiary Care Center. Blood. 120(21). 4681–4681. 1 indexed citations
20.
Olson, Sara H., Irene Orlow, Sharon Bayuga, et al.. (2008). Variants in hormone biosynthesis genes and risk of endometrial cancer. Cancer Causes & Control. 19(9). 955–963. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gabrielle T. Prince Breakdown of academic impact, for papers by Peter Tan Breakdown of academic impact, for papers by Raphael Teipel Breakdown of academic impact, for papers by Leah Gehrs Breakdown of academic impact, for papers by Shaowei Qiu Breakdown of academic impact, for papers by Lars Fransecky Breakdown of academic impact, for papers by Jean‐Valère Malfuson Breakdown of academic impact, for papers by Carmen Martínez‐Chamorro Breakdown of academic impact, for papers by Kaiyang Ding Breakdown of academic impact, for papers by Timon Hansen
Rankless by CCL
2026